Clinical Rheumatology

, Volume 32, Issue 2, pp 281–283

Rituximab-induced regression of CREST-related calcinosis

  • Dayane Raquel de Paula
  • Fabiane Barbero Klem
  • Pedro Gabriel Lorencetti
  • Carolina Muller
  • Valderilio Feijó Azevedo
Case Based Review

DOI: 10.1007/s10067-012-2124-z

Cite this article as:
de Paula, D.R., Klem, F.B., Lorencetti, P.G. et al. Clin Rheumatol (2013) 32: 281. doi:10.1007/s10067-012-2124-z

Abstract

About a quarter of sclerodermic patients present calcinosis. However, patients with limited form of the disease are more likely to have calcinosis than patients with diffuse form. We report a case of a 54-year-old female patient with limited cutaneous scleroderma using rituximab (RTX) to treat lung fibrosis and arthritis. Into RTX treatment, she also had a complete resolution of calcinosis in her hands. The patient reported improvement in dyspnea and synovitis after two courses of RTX (four weekly infusions 375 mg/m2 each). After 7 months of the first infusion, the calcinosis in her fingers had a complete remission, especially the right thumb. Based on current evidences, we discuss the use of rituximab as a promising therapy to treat not only lung disease but also calcinosis in patients with scleroderma.

Keywords

Calcinosis Rituximab Scleroderma Treatment 

Copyright information

© Clinical Rheumatology 2012

Authors and Affiliations

  • Dayane Raquel de Paula
    • 1
  • Fabiane Barbero Klem
    • 1
  • Pedro Gabriel Lorencetti
    • 1
  • Carolina Muller
    • 2
  • Valderilio Feijó Azevedo
    • 3
    • 4
  1. 1.Faculty of MedicineFederal University of ParanáCuritibaBrazil
  2. 2.Scleroderma Outpatient Clinic, Hospital de ClinicasFederal University of ParanáCuritibaBrazil
  3. 3.Hospital de ClinicasFederal University of ParanáCuritibaBrazil
  4. 4.Edumed-Health Research and EducationCuritibaBrazil

Personalised recommendations